Tanabe Eyes US NDA For Dersimelagon Following Positive Phase III Results In Rare Derma Disorders

Potential First Oral Drug For EPP/XLP

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.